Count | |
| 1 | |
| 29 | |
| 1 | |
| 2813 | |
| 3 | |
| 8 | |
| 1 | |
| 3 | |
| 8 | |
| 9 | |
| 265 | |
| 301 | |
| 1 | |
| 1 | |
| 20 | |
| 1 | |
| 8 | |
| 725 | |
| 22 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 20 | |
| 1 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
*Pyridines/pharmacology/*supply & distribution/therapeutic use | 1 |
| 1 | |
| 1 | |
| 1 | |
Zalcitabine/analogs & derivatives/supply & distribution/*therapeutic use | 1 |
Physicians/statistics & numerical data/*supply & distribution | 1 |
Ethinyl Estradiol/*adverse effects/chemistry/supply & distribution | 1 |
Progesterone Congeners/*adverse effects/chemistry/supply & distribution | 1 |
Ventilators, Mechanical/statistics & numerical data/supply & distribution | 1 |
| 1 | |
| 1 | |
| 18 | |
| 3 | |
| 1 | |
| 1 | |
| 7 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 4 | |
| 22 | |
| 4 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 3 | |
| 2 | |
| 1 | |
| 41 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 12 | |
| 10 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 2 | |
| 2 | |
| 63 | |
| 1 | |
| 5 | |
| 2 | |
| 1 | |
| 1 | |
| 4 | |
| 1 | |
| 1 | |
| 5 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 14 | |